Juno Pharma Canada
Biosimilar developer, Canada. 1 development product across 1 molecule: enoxaparin sodium.
First approval in the Atlas: Oct 2020, Noromby, enoxaparin sodium (HC)
FDAproducts approved0
EMAproducts approved0
PMDAproducts approved0
HCproducts approved1
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Enoxaparin sodium | Noromby | · | · | · | Oct 2020 | · | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- HCOct 2020Noromby, enoxaparin sodium
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.